{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T12:18:32Z","timestamp":1795263512185,"version":"4.10.3"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T00:00:00Z","timestamp":1708041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,16]]},"abstract":"<jats:p>In recent years, direct-acting antivirals (DAAs) have dramatically improved the sustained virological response (SVR) rates in chronic hepatitis C (CHC) patients with their favorable safety and efficacy. However, there is a lack of data on the long-term prognosis of DAA therapy for CHC patients after achieving SVR in the real world. The aim of this study was to evaluate the long-term clinical prognosis of patients with chronic hepatitis C treated by DAA after achieving SVR. This study was a single-center, retrospective, observational study that included 243 CHC patients who reached SVR after DAA treatment in the Third Affiliated Hospital of Sun Yat-sen University from January 2017 to December 2021, with a median follow-up period (FUP) of 24 months, to assess the long-term prognosis and clinical outcomes of CHC patients who reached SVR by DAA treatment. A total of 243 patients were enrolled in this study, 151 patients were male, the mean age of this study was 46.7\u2005\u00b1\u200512.3 years old, and 23.0% (n<jats:italic toggle=\"yes\">\u2005<\/jats:italic>=\u200556) patients were cirrhosis in the baseline. At the end of follow-up, 9 patients (3.7%) progressed to hepatocellular carcinoma (HCC), and patients with cirrhosis at baseline (n<jats:italic toggle=\"yes\">\u2005<\/jats:italic>=\u20055) had a significantly higher risk of HCC compared with noncirrhotic patients (n\u2005=\u20054; OR\u2005=\u20054.485, 95% CI: 1.162\u201317.318, <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u2005.029); 2.9% patients (n\u2005=\u20057) relapsed at the median FUP of 12 months, and patients with genotype 3b had a significantly higher risk of relapsing than those without genotype 3b (OR\u2005=\u200518.48, <jats:italic toggle=\"yes\">P\u2005<\/jats:italic>=\u2005.002, 95% CI: 2.866\u2013119.169). ALT, AST, and ALB all showed improvement at the end of treatment compared with the baseline, remaining at normal levels during FUP meanwhile. The DAA-induced SVR was durable, with conspicuous improvement in clinical outcomes. Nevertheless, patients, especially patients with cirrhosis, still exist the risk of appearance of HCC after reaching SVR. Therefore, regular surveillance and monitoring is necessary even after patients reached SVR.<\/jats:p>","DOI":"10.1097\/md.0000000000037212","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T19:07:19Z","timestamp":1708110439000},"page":"e37212","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Five-year follow-up of sustained virological response with hepatitis C infection after direct-acting antiviral therapy: A single-center retrospective study"],"prefix":"10.1097","volume":"103","author":[{"given":"Mengyue","family":"Li","sequence":"first","affiliation":[{"name":"Department of Infectious diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Wang","sequence":"additional","affiliation":[{"name":"GuangZhou International Travel Health Care Center, Guangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0266-7506","authenticated-orcid":false,"given":"Chaoshuang","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Infectious diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"e0080","DOI":"10.1097\/HC9.0000000000000080","article-title":"Reengagement strategies for hepatitis C patients lost to follow-up: a randomized clinical trial.","volume":"7","author":"Morales-Arraez","year":"2023","journal-title":"Hepatol Commun"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"e0246836","DOI":"10.1371\/journal.pone.0246836","article-title":"Temime L. Hepatitis C virus infection and risk factors among patients and health-care workers of Ain Shams University hospitals, Cairo, Egypt.","volume":"16","author":"Anwar","year":"2021","journal-title":"PLoS One"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"270","DOI":"10.35772\/ghm.2021.01080","article-title":"Prevalence, diagnosis, and treatment of hepatitis C in Mainland China.","volume":"3","author":"Mei","year":"2021","journal-title":"Glob Health Med"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"575","DOI":"10.3350\/cmh.2021.0155","article-title":"Sofosbuvir\/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Mol Hepatol"},{"issue":"Suppl 1","key":"R6-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma.","volume":"73","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: real-world experience from the HCV-TARGET cohort.","volume":"73","author":"Verna","year":"2020","journal-title":"J Hepatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12985-017-0708-6","article-title":"SVR Rates of HCV-infected population under PEG-IFN-\u03b1\/R treatment in Northwest China.","volume":"14","author":"Li","year":"2017","journal-title":"Virol J"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/jvh.13701","article-title":"Randomized clinical trial: direct-acting antivirals as treatment for hepatitis C in people who inject drugs. Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.","volume":"29","author":"Beer","year":"2022","journal-title":"J Viral Hepat"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e0232773","DOI":"10.1371\/journal.pone.0232773","article-title":"Treatment and re-treatment results of HCV patients in the DAA era.","volume":"15","author":"Piecha","year":"2020","journal-title":"PLoS One"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.3390\/jcm12062195","article-title":"Outcomes and follow-up after hepatitis C eradication with direct-acting antivirals.","volume":"12","author":"Lynch","year":"2023","journal-title":"J Clin Med"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/jgh.15192","article-title":"High hepatitis C virus cure rates with approved interferon-free direct-acting antivirals among diverse mainland Chinese patients including genotypes 3a and 3b.","volume":"36","author":"Ji","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/liv.13629","article-title":"Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon\/ ribavirin-free treatment.","volume":"38","author":"Kozbial","year":"2018","journal-title":"Liver Int"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.","volume":"65","author":"Reig","year":"2016","journal-title":"J Hepatol"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents.","volume":"18","author":"Mendizabal","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3390\/jpm12091517","article-title":"Direct-acting antivirals for HCV treatment in decompensated liver cirrhosis patients: a systematic review and meta-analysis.","volume":"12","author":"An","year":"2022","journal-title":"J Pers Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/978-1-4939-8976-8_13","article-title":"Studying the hepatitis C virus-induced epigenetic signature after cure with direct-acting antivirals.","volume":"1911","author":"Perez","year":"2019","journal-title":"Methods Mol Biol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"102697","DOI":"10.1016\/j.bjid.2022.102697","article-title":"Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study.","volume":"26","author":"Pereira","year":"2022","journal-title":"Braz J Infect Dis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/liv.13596","article-title":"Long- term follow- up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.","volume":"38","author":"Reddy","year":"2017","journal-title":"Liver Int"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"e0026","DOI":"10.1097\/HC9.0000000000000026","article-title":"The burden of liver cirrhosis and underlying etiologies: results from the Global Burden of Disease Study 2019.","volume":"7","author":"Lan","year":"2023","journal-title":"Hepatol Commun"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1186\/s12879-021-06053-3","article-title":"Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.","volume":"21","author":"Quaranta","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jhep.2021.09.013","article-title":"Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.","volume":"76","author":"D\u2019Ambrosio","year":"2022","journal-title":"J Hepatol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/hep.27366","article-title":"Concordance of sustained virological response 4, 12 and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.","volume":"61","author":"Yoshida","year":"2015","journal-title":"Hepatology"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3389\/fmicb.2019.00535","article-title":"Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China.","volume":"10","author":"Lu","year":"2019","journal-title":"Front Microbiol"},{"key":"R26-20250504","first-page":"419","article-title":"Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China.","volume":"9","author":"Wang","year":"2021","journal-title":"J Clin Transl Hepatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:18:29Z","timestamp":1746328709000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000037212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,16]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000037212","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,16]]}}}